KemPharm, Inc. (KMPH): Price and Financial Metrics


KemPharm, Inc. (KMPH): $9.08

0.14 (+1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KMPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

KMPH POWR Grades


  • KMPH scores best on the Growth dimension, with a Growth rank ahead of 95.07% of US stocks.
  • KMPH's strongest trending metric is Momentum; it's been moving down over the last 33 weeks.
  • KMPH's current lowest rank is in the Stability metric (where it is better than 5.66% of US stocks).

KMPH Stock Summary

  • The price/operating cash flow metric for Kempharm Inc is higher than 98.45% of stocks in our set with a positive cash flow.
  • KMPH's price/sales ratio is 102.11; that's higher than the P/S ratio of 96.8% of US stocks.
  • With a year-over-year growth in debt of -97.5%, Kempharm Inc's debt growth rate surpasses only 1.8% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Kempharm Inc, a group of peers worth examining would be INFN, INSM, GPL, RDUS, and PZG.
  • Visit KMPH's SEC page to see the company's official filings. To visit the company's web site, go to kempharm.com.

KMPH Valuation Summary

  • In comparison to the median Healthcare stock, KMPH's price/earnings ratio is 224.66% lower, now standing at -45.5.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.

Below are key valuation metrics over time for KMPH.

Stock Date P/S P/B P/E EV/EBIT
KMPH 2021-08-31 106.2 23.1 -45.5 -305.7
KMPH 2021-08-30 101.8 22.1 -43.6 -292.3
KMPH 2021-08-27 101.4 22.0 -43.4 -291.2
KMPH 2021-08-26 101.5 22.1 -43.5 -291.6
KMPH 2021-08-25 105.1 22.8 -45.0 -302.2
KMPH 2021-08-24 109.4 23.8 -46.9 -315.3

KMPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KMPH has a Quality Grade of B, ranking ahead of 91.07% of graded US stocks.
  • KMPH's asset turnover comes in at 0.451 -- ranking 101st of 677 Pharmaceutical Products stocks.
  • ACUR, NAII, and EGRX are the stocks whose asset turnover ratios are most correlated with KMPH.

The table below shows KMPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.451 1.000 -0.427
2021-03-31 0.745 1.000 -0.609
2020-12-31 1.218 1.000 -0.410
2020-09-30 1.146 1.081 -0.400
2020-06-30 1.958 1.000 -0.069
2020-03-31 1.318 1.000 -0.222

KMPH Price Target

For more insight on analysts targets of KMPH, see our KMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.00 Average Broker Recommendation 1.75 (Moderate Buy)

KMPH Stock Price Chart Interactive Chart >

Price chart for KMPH

KMPH Price/Volume Stats

Current price $9.08 52-week high $22.08
Prev. close $8.94 52-week low $5.07
Day low $8.81 Volume 783,200
Day high $9.12 Avg. volume 2,014,299
50-day MA $9.97 Dividend yield N/A
200-day MA $10.40 Market Cap 319.20M

KemPharm, Inc. (KMPH) Company Bio


KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.


KMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH ), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 9:00 a.m., ET on September 13, 2021, and can be accessed via the conference''s virtual platform by registered conference attendees. Details of the presentation are as follows: Event: H.C. Wainwright 23rd Annual Global Investment Conference Full story available on Benzinga.com

Benzinga | September 9, 2021

KemPharm Appoints Tamara A. Seymour to Board of Directors

CELEBRATION, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee.

Intrado Digital Media | August 18, 2021

KemPharm Reports Second Quarter 2021 Financial Results

Corporate and Regulatory Highlights

Intrado Digital Media | August 12, 2021

How to Pick the Best Small Cap Biotech Stocks to Buy

Investing in biotech stocks isn’t for the faint of heart, but these can be some of the most lucrative equities on the market.

kiernanfitzsimons on InvestorPlace | August 10, 2021

Costochondritis Treatment Market Recent Trends, Future Industry Growth Analysis Forecasts To 2027| KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma

Costochondritis is an inflammation of the cartilage that links the ribs to the sternum, often known as chest wall pain. Costochondritis has no known etiology, but it is most commonly caused by an injury, certain types of arthritis, joint inflection,

OpenPR | August 9, 2021

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo 0.22%
3-mo -35.56%
6-mo 0.22%
1-year -18.99%
3-year -87.39%
5-year -87.47%
YTD -18.93%
2020 84.55%
2019 -78.69%
2018 -56.05%
2017 37.29%
2016 -85.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8465 seconds.